Engflag

Hepatect

Quick links to important sections

Hepatect

Hepatect_L

Treatment option: Hepatitis, Blood Transfusion

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hepatect

What is Hepatect? An Overview

Property Description
Active Ingredient Human Hepatitis B Immunoglobulin
Pharmacological Class Specific Hyperimmune Globulin
Form Solution for Intravenous Infusion
Common Use Prevention of HBV recurrence/infection (Prophylaxis)
Origin Pooled Human Plasma

Hepatect is a highly specialized medication used for passive immunization, providing immediate, protective antibodies against the Hepatitis B virus (HBV). It is categorized as a specific hyperimmune globulin and is clinically recognized for its critical role in immediate post-exposure protection.

What Type of Medicine is Hepatect?

Hepatect is a targeted medication that provides ready-made antibodies to the body, offering immediate, passive immunity against the Hepatitis B virus.

It is classified as a Human Hepatitis B Immunoglobulin. This approach differs from active immunization (like a vaccine) because it delivers a concentrated dose of protective antibodies directly, rather than relying on the body to produce its own defenses. This immediate protection is utilized in post-exposure and post-transplant settings.

Is Hepatect Natural or Synthetic? (Composition and Origin)

Hepatect is a natural, plasma-derived product, highly purified from the blood of healthy human donors who have a high level of protective Hepatitis B antibodies.

The active component is sourced from carefully screened human plasma. This purification process, which is strictly regulated, ensures the final product is a highly specific, sterile solution for infusion. Because it is a plasma derivative, its production involves extensive screening and processing steps to minimize risk and ensure purity.

What is the General Purpose of Hepatect Treatment?

The general purpose of Hepatect is to prevent or reduce the risk of Hepatitis B virus (HBV) infection or reinfection in highly vulnerable individuals.

The core use of this medication is prophylaxis (preventive treatment). This includes protecting patients who receive liver transplants from recurrence of the virus and providing immediate protection after potential exposure. By neutralizing circulating virus particles, Hepatect establishes a protective shield essential during critical periods when a patient's natural immune response may not be fast or strong enough.

Regulatory References

  1. NIH

What side effects are possible with Hepatect?

Possible Side Effects and Safety Information

Hepatect (Human Hepatitis B Immunoglobulin) is generally well-tolerated, but like all medicines, it can cause side effects. Most reported adverse reactions are mild to moderate in nature.

Common and Occasional Reactions

The most frequently reported side effects associated with Hepatect and other human normal immunoglobulin products include:

  • Infusion-related reactions: Symptoms such as headache, chills, fever (pyrexia), malaise (general feeling of being unwell), nausea, and vomiting are often related to the rate of infusion. Your healthcare provider will monitor the infusion rate closely to minimize these effects.
  • Hypotension (low blood pressure)
  • Skin reactions: This may include rash or pruritus (itching).
  • Musculoskeletal pain: Reported as arthralgia (joint pain) or back pain.

Important Safety Information

Allergic Reactions:

  • Hypersensitivity and anaphylactic reactions (severe allergic reactions) are rare but possible, even in patients who have tolerated previous treatments. Symptoms requiring immediate medical attention include hives, swelling of the face or throat, trouble breathing, dizziness, or a sudden fall in blood pressure.
  • Hepatect contains a small amount of Immunoglobulin A (IgA). Patients with a severe IgA deficiency who have IgA antibodies may be at increased risk of an anaphylactic reaction.

Thromboembolic Events:

  • In very rare cases, thromboembolic events such as myocardial infarction (heart attack), stroke, or deep vein thrombosis (blood clots) have been reported, particularly in patients with pre-existing risk factors (e.g., advanced age, history of vascular disease, or immobility). Adequate hydration and monitoring are essential to minimize this risk.

Interference with Vaccines:

  • Immunoglobulin administration may reduce the effectiveness of certain live attenuated virus vaccines (such as measles, mumps, rubella, and varicella) for a period of up to three months. Consult your physician regarding the timing of any live vaccinations following Hepatect treatment.

Contraindications:

  • You should not receive Hepatect if you have a known allergy to human immunoglobulin or any of the product's components, or if you have a selective IgA deficiency with antibodies against IgA.

Overdose and Emergency Response

Overdose and When to Seek Help

Official Overdose Information

The official regulatory documents for Hepatect (Human Hepatitis B Immunoglobulin for intravenous use) explicitly state that the consequences of an overdose are not known. This means there are no documented overdose presentations, symptom clusters, or specific dose levels associated with overdose risk officially listed in the product labeling.

Since the consequences of an overdose are not known, there are no specific emergency actions or procedural instructions for overdose situations included in the official government regulatory texts. There is also no formal severity classification of overdose provided by regulators.

When Urgent Medical Attention is Required

While specific overdose symptoms are not documented, immediate medical attention is required for any signs of a severe or systemic reaction, which may occur during or after administration of immunoglobulin products. Urgent professional help must be sought immediately if any signs of anaphylactic shock or severe hypersensitivity are suspected.

Signs that require immediate medical review include, but are not limited to:

  • Sudden drop in blood pressure (hypotension)
  • Rapid heart rate (tachycardia)
  • Swelling of the face, lips, or throat (angioedema)
  • Difficulty breathing or wheezing
  • Severe nausea or vomiting
  • Fever, chills, or malaise (general feeling of being unwell)

In the event of any severe adverse reaction, the infusion must be stopped immediately, and standard medical treatment for shock should be implemented as needed. Patients must be carefully monitored during and immediately following the infusion for the detection of adverse signs.

Therapeutic Uses of Hepatect

What Hepatect Treats: Main Uses and Benefits

Hepatect is used to provide supportive, temporary protection against the Hepatitis B virus (HBV) and may assist with managing the risk of serious health issues related to infection. It is relevant in specific high-risk scenarios where additional symptomatic support is needed. Its main therapeutic areas include post-exposure symptomatic management and liver transplant support.

The medication is commonly used in three main contexts: addressing the risk of infection following accidental exposure to HBV in non-immune individuals, supporting patients in conditions marked by increased physiological stress after a liver transplant due to HBV, and assisting with managing the risk of infection in newborns whose mothers are HBV-positive.

“This approach is relevant in contexts marked by increased discomfort or tension, and assists with maintaining functional stability.”

Key Therapeutic Benefits

In each clinical scenario, the treatment provides a temporary protective effect that may assist with managing the risk of the initial infection from becoming established. This supports easing the symptomatic burden associated with acute manifestations like severe fatigue or jaundice. For transplant patients, it contributes to maintaining the functional stability of the new liver by addressing the risk of the virus re-infecting the new organ.

Quick Fact: Support for Managing Infection Risk The medication supports patients during difficult episodes by easing distress and is applied across domains where additional symptomatic support is needed.

Eligibility and Restrictions for Use

Hepatect's eligibility rules are strictly defined by regulatory authorities based on population status and pre-existing conditions. These rules determine who is allowed to use the medicine and who is formally prohibited.

Populations Allowed

Use is approved and established for several high-risk groups to prevent Hepatitis B Virus (HBV) infection. This includes newborns of mothers who are HBsAg-positive, non-immune individuals following a single, acute HBV exposure, and patients undergoing liver transplantation for HBV-related liver disease.

Contraindications and Restrictions

The medicine is contraindicated in patients with a known history of hypersensitivity to human immunoglobulins or any excipients in the formulation. This includes individuals with Selective IgA deficiency who have documented antibodies against IgA.

Use requires caution in patients with certain pre-existing conditions, particularly those with risk factors for thrombotic events (such as advanced age or severe dehydration) and individuals with impaired renal function.

Age and Physiological States

Use is permitted with caution during both pregnancy and lactation, as clinical experience suggests no expected harmful effects on the fetus or breastfed infant. The medicine is approved for the entire age range, from newborns through the adult population, within its specific preventive indications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Hepatect (Human Hepatitis B Immunoglobulin) focuses primarily on pharmacodynamic interactions and administration constraints, as documented by regulatory authorities.

Pharmacodynamic Interactions and Administration Restrictions

Interacting Substance/Class Official Interaction Pattern
Live Attenuated Virus Vaccines (e.g., Measles, Mumps, Rubella) Administration of immunoglobulin may impair the efficacy of the vaccine, necessitating a mandatory timing separation.
Loop Diuretics (e.g., Furosemide) Concomitant use must be avoided due to a documented increased risk of adverse reactions associated with intravenous immunoglobulin administration.

The effect on active immunization is a clinically significant interaction where the passively transferred antibodies antagonize the vaccine's intended effect. Therefore, vaccination with live attenuated vaccines should be deferred until approximately three months following Hepatect administration. In the case of measles vaccine, the interference may last up to one year.

Procedural and Metabolic Notes

Hepatect is strictly prohibited from being mixed with other medicinal products or any other Intravenous Immunoglobulin (IVIg) products, constituting a procedural constraint for safe use. No specific pharmacokinetic interactions involving cytochrome P450 (CYP) enzymes or drug transporters are formally documented in the regulatory labeling. The requirement to avoid loop diuretics is particularly relevant for managing risk in specific patient populations, such as those with advanced age or pre-existing renal impairment.

Mechanism of Action

️ Neutralizing the Circulating Virus

The mechanism of Hepatect is anchored in passive humoral immunity, acting via direct molecular neutralization. The medication contains pre-formed, high-titer anti-HBs antibodies (∿Immunoglobulin G∿) that swiftly bind to the Hepatitis B Surface Antigen (∿HBsAg∿) on circulating viral particles. This binding immediately renders the virus non-infectious, initiating the systemic clearance pathway and resulting in a decrease in the concentration of infectious HBV in the bloodstream.

⏸️ Blocking Viral Entry into Liver Cells

Neutralization leads to a critical cascading effect: the steric blockade of the viral entry pathway. By coating the virus, the antibodies physically obstruct the region required for the virus to attach to the ∿NTCP receptor∿ on the liver cell (∿hepatocyte∿) membrane. This interference is the ultimate step that interrupts the viral replication cycle, preserving hepatocyte integrity and preventing newly released viruses from establishing new, systemic infections.

Dosage and Administration Information

How to Use Hepatect: Official Administration Guidelines

Hepatect (Human Hepatitis B Immunoglobulin) is a sterile solution intended for use only as an Intravenous (IV) Infusion. It must not be administered by any other route, such as intramuscular injection or orally.

Administration and Preparation

Procedural Step Instruction
Route Intravenous Infusion Only
Preparation Bring the solution to room temperature or body temperature before use. Do not dilute. Do not use if the solution appears cloudy or has deposits.
Infusion Rate Infusion must begin slowly (e.g., 0.1 ml/kg/hr for adults/older children). If well tolerated, the rate may be gradually increased to a maximum of 1 ml/kg/hr. Newborns receive 2 ml over 5 to 15 minutes.
Monitoring Patients must be closely observed for at least 20 minutes following administration, and for one hour after the first infusion in certain high-risk patients.

Dosage and Schedule

Dosing of Hepatect is highly specific to the patient's indication and often relies on monitoring of serum anti-HBs antibody levels.

Context of Use Standard Labeled Dosing Regimen
Post-Liver Transplant Prophylaxis Initial dose: 10,000 IU peri-operatively, followed by 2,000–10,000 IU daily for the first 7 days. Maintenance dosing is adjusted to maintain anti-HBs levels (e.g., >100-150 IU/l).
Newborn Prevention 30–100 IU/kg, administered at birth alongside the first active vaccination.

For pediatric patients receiving post-transplant prophylaxis, the dose is adjusted based on body surface area (10,000 IU/1.73 m^2). The long-term course duration for post-transplant patients is determined by the need to continuously maintain protective antibody levels, which necessitates ongoing monitoring and dose adjustment.

Recent Clinical Evidence

Hepatect: Research Evidence Overview

Evidence for use in Preventing Recurrence after Liver Transplant

Research has extensively explored the use of Human Hepatitis B Immunoglobulin in patients who receive a liver transplant for illness caused by the Hepatitis B Virus (HBV). Research has focused on evaluating the immunoglobulin in strategies that address the potential for the virus to return to the new organ. Studies contributing to this evidence include long-term observational analyses and systematic reviews that examine combination regimens with antiviral medications.

Outcomes monitored in these populations often extend over many years and include tracking the rate at which HBV markers reappear, as well as graft survival and patient survival rates over long time intervals. Data show patterns related to maintaining specific antibody levels in the blood, which researchers monitor in relation to the rate of recurrence. Research is still evaluating the structural role of the immunoglobulin when used alongside highly potent new antiviral drugs.

Evidence for Immediate Protection in Newborns (Perinatal Prophylaxis)

Studies focusing on immediate administration involve newborn infants born to mothers who carry the Hepatitis B Virus. Research has explored the use of the immunoglobulin, given soon after birth, in combination with the standard HBV vaccine, in studies that evaluate infection rates. The research structure includes early clinical trials and large observational studies that monitor infants over several months. Research indicates that the combined approach was associated with specific serological outcomes, such as changes in the rate of long-term carrier status in the observed infants.

What Research Gaps and Uncertainties Remain

The broader evidence landscape contributes to understanding study outcomes, but some key questions persist. These include protocol heterogeneity regarding the optimal dose and frequency for long-term prophylaxis, and the exact contribution of the immunoglobulin when used in combination with modern antiviral drugs. Sample sizes were modest in some studies involving special or complex patient groups, meaning that data for certain groups remain insufficient for firm conclusions.

Key Studies & References

  1. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation (Turkish Gastroenterology Consensus)

Frequently Asked Questions (FAQ)

Common questions about Hepatect (FAQ)

Q: What is the purpose of Hepatect?

Hepatect is an immunoglobulin medication. It is used to prevent the re-infection of the liver with Hepatitis B in patients who have received a liver transplant for Hepatitis B-related liver failure. According to regulatory documents, it works by supplying antibodies against the Hepatitis B virus.

Q: Is Hepatect a vaccine for Hepatitis B?

No, Hepatect is not a vaccine. It is an immunoglobulin product that directly supplies already-formed antibodies against the Hepatitis B virus (HBV). Unlike vaccines, which prompt the body to create its own protection, Hepatect supplies pre-formed antibodies. Studies and official information indicate that this provides immediate, temporary protection.

Q: What is the active ingredient in Hepatect?

The active ingredient in Hepatect is human anti-Hepatitis B immunoglobulin. This substance is collected from the plasma of human donors who have a high level of antibodies against the Hepatitis B virus, as stated in the product information. This ingredient works by passively transferring those antibodies to the recipient.

Q: Is Hepatect a blood product?

Yes, Hepatect is classified as a blood product. It is made from human blood plasma, which is the liquid part of blood. Regulatory documents state that the human plasma is carefully screened and processed according to established safety procedures.

Q: How long does the protection from Hepatect last?

The official product information indicates that the protection provided by Hepatect is temporary. Because it is a passive antibody transfer, the levels of the protective antibodies decrease over time. Due to its temporary nature, Hepatect is typically administered as part of a regimen defined by the prescribing healthcare professional.

Q: Can Hepatect cure existing Hepatitis B infection?

No, Hepatect is not intended to cure an existing Hepatitis B infection. According to regulatory documents, its use is specifically for the prevention of re-infection in patients who have undergone a liver transplant due to Hepatitis B. It works by providing high levels of protective antibodies.

Q: What is an 'immunoglobulin'?

An immunoglobulin is another term for an antibody. Antibodies are special proteins produced by the immune system to identify and neutralize foreign objects, such as bacteria and viruses. Studies and official information state that Hepatect provides pre-formed antibodies against the Hepatitis B virus.

How should Hepatect be stored and disposed of?

How to Store and Dispose of Hepatect

Hepatect (Hepatitis B Immunoglobulin, Human) must be handled and stored according to specific regulatory conditions to maintain its stability and shelf-life.

Official Storage Requirements

Requirement Condition
Temperature Store in a refrigerator between 2°C and 8°C.
Freezing Must not be frozen.
Protection Store in the original outer carton to protect from light.
Child Safety Keep out of the sight and reach of children.

Disposal

Any unused or expired product must be disposed of strictly in accordance with local requirements for pharmaceutical waste. Disposal via household waste or wastewater is generally not permitted unless local regulations specifically advise it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBulgaria

flagCroatia (Hrvatska)

flagHungary

flagNorway

flagSpain

Equivalent of Hepatect found in:

A-Z Index: